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We investigated early phenotypes caused by familial
Alzheimer’s disease (fAD) mutations in isogenic
human iPSC-derived neurons. Analysis of neurons
carrying fAD PS1 or APP mutations introduced using
genome editing technology at the endogenous loci
revealed that fAD mutant neurons had previously un-
reported defects in the recycling state of endocytosis
and soma-to-axon transcytosis of APP and lipopro-
teins. The endocytosis reduction could be rescued
through treatment with a b-secretase inhibitor. Our
data suggest that accumulation of b-CTFs of APP,
but not Ab, slow vesicle formation from an endocytic
recycling compartment marked by the transcytotic
GTPase Rab11. We confirm previous results that
endocytosis is affected in AD and extend these to
uncover a neuron-specific defect. Decreased lipo-
protein endocytosis and transcytosis to the axon
suggest that a neuron-specific impairment in endo-
cytic axonal delivery of lipoproteins and other key
materials might compromise synaptic maintenance
in fAD.
INTRODUCTION
Alzheimer’s disease (AD) is a progressive and devastating neuro-
degenerative disorder that affects more than 30 million people
worldwide, including 11% of those over 65 years of age and
32% of those over 85 (Alzheimer’s Association, 2014). AD is
characterized by progressive cerebral dysfunction, memory
loss, synapse loss, and neuronal impairment leading to cell
death. To date, there are no disease-modifying treatments that
can cure or reduce the progression of AD. Genetically, AD is
segmented into two populations: sporadic AD (sAD), where the
underlying primary cause is not known, and rare autosomal-
dominant mutations causing familial AD (fAD) (Gatz et al.,Ce
This is an open access article und2006). The common pathological features of sAD and fAD
patients are the accumulation of senile plaques, composed
of aggregated amyloid-b (Ab), and neurofibrillary tangles
(NFTs), composed of hyper-phosphorylated tau (Spires-Jones
and Hyman, 2014). Importantly, many experimental findings
regarding AD have come from overexpression studies or studies
of non-neuronal cells that lack the unique polarization and
compartmentalization of neurons.
The amyloid cascade hypothesis of AD posits that extracel-
lular Ab fragments of proteolytically processed amyloid precur-
sor protein (APP) and intraneuronal tau accumulate abnormally
in sAD and fAD. These accumulations are proposed to drive
cellular stress, neurotoxicity, and, ultimately, synapse loss and
neurodegeneration (Toyn and Ahlijanian, 2014). Previous work
also reported apparent defects in early endocytosis in post-mor-
tem brains of AD patients (Cataldo et al., 2001; Ginsberg et al.,
2010). Complementary investigations in overexpression and
non-neuronal cellular models also pointed to defects in early
endocytosis and endocytic dysfunction driven not by Ab but,
instead, by b C-terminal fragments (b-CTFs) of APP (von Bar-
theld, 2004; Cataldo et al., 2000; Ginsberg et al., 2010; Karch
and Goate, 2015; Lee et al., 2010; Maxfield, 2014). In addition,
unbiased screens in non-neuronal cells consistently identified
regulators of endocytic trafficking as key to normal levels of
APP processing (Cataldo et al., 2000; Ginsberg et al., 2010;
Treusch et al., 2011). However, many of the key investigations
did not utilize normal expression levels of AD-related proteins
or did not fully examine sorting pathways in highly polarized neu-
rons. Thus, although several important insights into the role
of endocytosis in regulating APP processing and sorting have
been obtained from various cell models, little is known about
endocytosis-dependent trafficking in polarized human neurons
with mutations expressed at normal levels.
We tested whether isogenic induced pluripotent stem cell
(iPSC)-derived human neurons with fAD PS1 and APPmutations
induced by genome editing mutagenesis (transcription acti-
vator-like effector nuclease [TALEN] and clustered regularly
interspaced short palindromic repeats [CRISPR]/Cas9) at the
endogenous loci display amyloid-independent cellular traffickingll Reports 17, 759–773, October 11, 2016 ª 2016 The Authors. 759
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Figure 1. PS1DE9 iPSC-Derived Neurons Exhibit Altered Sub-cellular Distribution of APP
(A) PS1DE9 neurons have a gene dose-dependent increase in soma APP intensity. Data are represented as mean ± SEM of all cell values with 10 PS1WT/WT,
6 PS1WT/DE9, and 10 PS1DE9/DE9 biological replicates. (PS1WT/DE9, p < 0.05; PS1DE9/DE9, p < 0.0001). Scale bar, 20 mm.
(B) The surface intensity of APP is increased in PS1WT/DE9 and PS1DE9/DE9 (p < 0.01) neurons compared with PS1WT/WT. Scale bar, 5 mm.
(C) PS1WT/WT neurons exhibited minimal APP CTF staining in unpermeabilized cells and dramatically increased N-terminal fragment (NTF) staining when per-
meabilized. Data represent the mean ± SEM from two immunofluorescence experiments with two biological replicates per control (p = 0.0262). Scale bar, 5 mm.
(D) Average density of APP (PS1WT/DE9, p < 0.05; PS1DE9/DE9, p < 0.0001) and individual punctum intensities (PS1WT/DE9, p < 0.0001; PS1DE9/DE9, p < 0.0001) were
decreased in a gene dose-dependent manner in PS1DE9 axons. Data represent the pooled median values with Tukey whiskers from three immunofluorescence
experiments representing seven PS1WT/WT, four PS1WT/DE9, and six PS1DE9/DE9 biological replicates. Scale bar, 5 mm.
(E) A schematic of the microfluidic devices.
(legend continued on next page)
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and transport phenotypes, beyond the known effects on APP
processing, that could account for the development of fAD
(von Bartheld, 2004; Cataldo et al., 2000; Ginsberg et al., 2010;
Karch and Goate, 2015; Lee et al., 2010; Maxfield, 2014). Human
neurons expressing fAD mutant PS1 and APP at normal expres-
sion levels from the endogenous loci alter subcellular distribution
and trafficking of APP and internalized lipoprotein, leading to
elevated levels of APP in the soma and reduced levels in the
axons. The redistribution of APP is accompanied by the concur-
rent accumulation of Rab11 endosomal vesicles in the neuronal
soma and reduced Rab11 axonal staining, suggesting that the
reduction in axonal APP and lipoproteins can be explained by
reduced Rab11-dependent soma-to-axon transcytosis and de-
fects in the recycling endosome (Ascan˜o et al., 2009; von Bar-
theld, 2004; Buggia-Pre´vot et al., 2014). Knockdown of Rab11
also leads to reductions in APP axonal density and lipoprotein
endocytosis and transcytosis. Our study reveals that a common
early defect among fAD PS1 and APP mutations is APP b-CTF
accumulation-induced impairment of a key neuron-specific
traffic pathway, soma-to-axon transcytosis, caused by defects
in the recycling endosome.
RESULTS
The PS1DE9 Mutation Increases APP in the Soma of
Human Neurons and Decreases APP in Axons
PS1 has been reported to have a role in APP trafficking in pri-
mary neurons and in non-neuronal cell types (Burns et al.,
2003; Cai et al., 2003; Gandy et al., 2007; Zhang et al., 2006).
PS1 knockout has been reported to increase cell surface APP
(Leem et al., 2002), whereas PS1 fAD mutations have been
shown to delay APP arrival at the cell surface (Cai et al., 2003;
Gandy et al., 2007). To determine whether the PS1DE9 mutation
affects APP localization in human neurons, we generated
purified neurons from isogenic iPSC lines from wild-type
(PS1WT/WT) and lines heterozygous (PS1WT/DE9) and homozy-
gous (PS1DE9/DE9) for the PS1DE9 mutation (Woodruff et al.,
2013). We stained with an APP antibody that has minimal
staining in cells from APP knockout mice (Guo et al., 2012;
Weissmiller et al., 2015). We found that PS1WT/DE9 and
PS1DE9/DE9 neurons exhibited a modest but significant increase
in intracellular APP staining in the cell body (Figure 1A). To deter-
mine whether APP was also increased on the surface of PS1DE9
neurons, we stained unpermeabilized purified neurons with an
N-terminal APP antibody that recognizes the extracellular
portion of APP (22C11) (Figure 1B). We observed increased
APP on the soma surface of PS1DE9 neurons (Figure 1B). As a
control, we also stained unpermeabilized neurons with a C-ter-
minal antibody and observed minimal staining, as would be
expected because the C terminus of APP would not be present
on the cell surface (Figure 1C).
We previously published that PS1DE9 human neurons do not
exhibit changes in total levels of full-length APP, although there(F) sAPPa/b ratios in soma were not statistically different (p = 0.9614), but the ratio
Shown are relative amounts of secreted sAPPa and sAPPb in PS1DE9/DE9 axons c
levels (p = 0.0540), in PS1DE9/DE9 axons. Data represent four PS1WT/WT and four
See also Figure S1.are increases in the APP CTFs (Woodruff et al., 2013). The in-
crease in soma APP suggests that APP CTFs are accumulating
in the soma of purified neurons and/or that APP is missorted,
possibly at the expense of axonal APP. We therefore assessed
APP staining in the axons of PS1DE9 neurons. To ensure that
we were quantifying staining in axons and not dendritic pro-
cesses, we made use of microfluidic compartments, which
separate axons from the bulk somatodendritic population (Fig-
ure 1E; Niederst et al., 2015; Selfridge et al., 2015; Taylor et al.,
2005). Neurons grown in microfluidic devices extend long pro-
cesses into the axonal space that do not stain for the somato-
dendritic marker Map2 and that do stain for the axonal marker
neurofilament-H (SMI31) (Selfridge et al., 2015; Figure 1E; Fig-
ure S1A). We observed that PS1DE9 axons grown in microfluidic
devices have decreased axonal APP puncta and APP punctum
intensity (Figure 1D); this decrease is sensitive to PS1DE9 gene
dose.
To further characterize APP fragments that are present in
axons, we also measured soluble APP (sAPP) fragments,
sAPPa and sAPPb. To quantify secreted sAPP, we plated neu-
rons in compartments and allowed them to extend their axons
into the axonal space. We then performed a full medium
change, kept the axons in fluidic isolation, and harvested
media from the soma and axon sides. When we measured
the sAPPa/sAPPb ratio from the soma side of the cultures,
we observed no significant differences between PS1WT/WT
and PS1DE9/DE9 genotypes (Figure 1F). Additionally, there
were no significant differences in the total levels of sAPPa
or sAPPb from the soma side (Figure S1B). However, when
we quantified the sAPPa/sAPPb ratio from axons only, we
observed a significant increase from the PS1DE9/DE9 axons
compared with PS1WT/WT (Figure 1F). Upon quantification of
the total levels of sAPPa and sAPPb, we determined that the
ratio was increased in PS1DE9/DE9 axons primarily because of
a reduction in sAPPb (Figure 1F). To test whether the pheno-
typic differences we observed in PS1DE9 neurons might be
due to differences in neuronal subtypes in our cultures, we
stained neurons of each genotype with the neuronal subtype
markers gamma-aminobutyric acid (GABA), GAD65/67, and
vesicular glutamate transporter (vGlut) (Figure S1C). We found
no significant differences in the proportion of cells that stained
positive for GABA, GAD65/67, or vGlut between different ge-
notypes (Figure S1C).
Rab11 Distribution Is Altered in PS1DE9 Neurons
There are at least two pathways by which APP can be deliv-
ered to the axon. The first is by direct delivery from the
trans-Golgi network (TGN), and the second is by an indirect
pathway where APP first arrives at the cell surface of the so-
matodendritic compartment and then undergoes endocytosis
and sorting to the axon. The indirect pathway is a process
known as transcytosis, and multiple cargos, including TrkA
(Ascan˜o et al., 2009) and L1/NgCAM (Anderson et al., 2005;of axonally secreted sAPPa/bwas increased in PS1DE9/DE9 axons (p = 0.0199).
ompared with PS1WT/WT. sAPPb levels are reduced (p = 0.0056), but not sAPPa
PS1DE9/DE9 biological replicates.
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Figure 2. PS1DE9/DE9 Neurons Exhibit Altered Rab11 Distribution
(A) PS1WT/WT neurons exhibited a distinct punctate pattern of Rab11 staining in soma, and PS1DE9/DE9 neurons had a marked accumulation of Rab11 in
soma (arrowheads). Quantification of staining showed that soma Rab11 intensity (PS1WT/DE9, p = 0.3215; PS1DE9/DE9, p < 0.0001), punctum count (PS1WT/DE9,
p = 0.5876; PS1DE9/DE9, p < 0.0001), and punctum area (PS1WT/DE9, p = 0.6791; PS1DE9/DE9, p < 0.0001) were all significantly increased in PS1DE9/DE9
neurons. Data represent the mean ± SEM or median with Tukey whiskers from four PS1WT/WT, four PS1WT/DE9, and four PS1DE9/DE9 biological replicates. Scale
bar, 20 mm.
(legend continued on next page)
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Yap et al., 2008), have been demonstrated to be sorted along
this pathway in neurons.
An endocytic regulator that functions at the intersection of
the TGN and transcytotic pathways is the Rab GTPase Rab11
(Welz et al., 2014). Rab11 has a well-established role in medi-
ating the recycling of many receptors, including the trans-
ferrin receptor (Ullrich et al., 1996), and low-density lipoprotein
(LDL) receptors (Sakane et al., 2010; Takahashi et al., 2007).
In addition to its role in recycling, Rab11 has also been shown
to mediate transcytosis in epithelial cells and neurons. Specif-
ically in neurons, TrkA receptors undergo Rab11-dependent
transcytosis to the axon (Ascan˜o et al., 2009; Lazo et al.,
2013). Rab11 may also be involved in trafficking of BACE1 to
the axon (Buggia-Pre´vot et al., 2014), colocalizes with some
APP in axons (Niederst et al., 2015), and was recently identified
in an unbiased Rab GTPase screen in non-neuronal cells as
a regulator of Ab and sAPPb production (Udayar et al., 2013).
Intriguingly, presenilins have also been reported to interact
directly with Rab11 through their hydrophilic loop (Dumanchin
et al., 1999).
To determine whether Rab11 could be playing a role in the
reduction of axonal APP in PS1DE9 cells, we stained neurons
with a Rab11 antibody and measured Rab11 in the somatoden-
dritic and axonal compartments. The Rab11 staining was
reminiscent of the altered APP distribution such that PS1DE9/DE9
neurons exhibited increased soma Rab11 intensity, Rab11
puncta, and Rab11 punctum area (Figure 2A). In axons, both
the PS1WT/DE9 and PS1DE9/DE9 genotypes had decreased
Rab11 punctum density and punctum intensity (Figure 2B).
In support of a role of Rab11-dependent trafficking of APP to
the axon, short hairpin RNA (shRNA)-mediated knockdown of
Rab11 on the soma side of neurons grown inmicrofluidic devices
resulted in an40% reduction in APP axonal density (Figure 2C).
In keeping with a transcytotic route of APP to the axon, somato-
dendritic inhibition of endocytosis with Dynasore led to reduced
APP (25% less) and Rab11 (40% less) density in axons
(Figure 2D).
Previous publications have implicated alterations in early en-
dosomes and lysosomes in PS1 knockout cells (Coen et al.,
2012; Lee et al., 2010; Neely et al., 2011). We therefore looked
at the early endosome effector EEA1 and the lysosomal marker
Lamp2 even though they are not thought to traffic substantially
to axons (Wilson et al., 2000). Despite evidence in the literature
that early endosomes and lysosomes are dramatically affected
in fAD and sAD, EEA1 and Lamp2 staining in PS1DE9 neurons
was not obviously different, suggesting that they are not play-
ing an active role in sorting APP to the axon (Figures S2A
and S2B).(B) Quantification of Rab11 in axons. Rab11 density (PS1WT/DE9, p = 0.0003; PS1
p < 0.0001) were reduced in a dose-dependent manner in PS1DE9 neurons. Data r
PS1WT/DE9, and five PS1DE9/DE9 biological replicates. Scale bar, 5 mm.
(C) Knockdown of Rab11a diminished APP to60% of PS1WT/WT levels. Data rep
PS1WT/WT biological replicates (Rab11 density, p < 0.0001; Rab11 intensity, p <
(D) Inhibition of soma endocytosis resulted in an 50% decrease in Rab11 densit
Data represent the mean ± SEM or median with Tukey whiskers from axons of f
replicates (Rab11 density, p < 0.0001; Rab11 intensity, p < 0.0001; APP density
See also Figure S2.The PS1DE9 Mutation Decreases Endocytosis and
Transcytosis of APP and LDL
Because we observed alterations in the subcellular distribution
of both APP and Rab11 in PS1DE9 neurons, we investigated
whether endocytosis and/or transcytosis could account for
the APP localization changes. To assess endocytosis of APP,
we treated purified neurons with an N-terminal APP antibody
(22C11) and allowed cells to internalize the antibody for
30 min, 2 hr, or 4 hr and fixed cells at each of those time points.
We then stained with a secondary antibody and quantified the
amount of APP endocytosis at each time point (Figure 3A). We
observed a decrease in APP puncta in the PS1DE9/DE9 genotype
starting at 30 min compared with PS1WT/WT, and this decrease
was more prominent at both 2 and 4 hr (Figure 3A). The
PS1WT/DE9 genotype also exhibited decreased APP puncta
compared with PS1WT/WT at the 2- and 4-hr time points. As a
control to confirm whether the APP antibody was being endocy-
tosed uniquely via antigen binding, we performed an endocy-
tosis assay with a non-specific antibody and found minimal
uptake (Figure S3A). To assess whether this endocytosis defect
was specific to APP or common to other cargo, we also
measured the uptake of fluorescently labeled LDL at 30 min,
1 hr, 2 hr, and 4 hr (Figure 3B). Similar to what was observed
with APP, LDL punctum intensity and LDL punctum density
were reduced in PS1WT/DE9 and PS1DE9/DE9 neurons at 2 hr and
4 hr (Figure 3B). To test whether the differences observed were
due to a non-specific defect in endocytosis, we also quantified
the uptake of fluorescently labeled dextran as a marker of bulk
endocytosis. We did not observe any significant differences in
dextran endocytosis at any time point (Figure 3C). Additionally,
we quantified endocytosis of fluorescently labeled transferrin,
and, similar to dextran, we did not observe any significant dif-
ferences (Figures S3B and S3C).
We measured transcytosis of APP and LDL by growing
neurons in microfluidic compartments. The axon side of the
compartment was kept in fluidic isolation from the soma side,
and APP antibody or labeled LDL was added only to the soma
side. Transcytotic delivery of cargo from the soma to the axon
is a relatively slow process because internalized cargo has to
travel long distances (on the order of millimeters in cultured neu-
rons). After 4 hr of endocytosis, cells were fixed, and we quanti-
fied the amount of anterogradely transcytosed APP by using
an anti-mouse secondary antibody; fluorescent LDL was
measured directly (Figures 3D and 3E). We observed that both
the PS1WT/DE9 and PS1DE9/DE9 genotypes exhibited decreased
APP axonal density and APP intensity after 4 hr of transcytosis
(Figure 3D). Similarly, LDL axonal density and intensity were
also decreased in PS1WT/DE9 and PS1DE9/DE9 axons after 4 hrDE9/DE9, p < 0.0001) and punctum intensity (PS1WT/DE9, p < 0.0001; PS1DE9/DE9,
epresent the mean ± SEM or median with Tukey whiskers of six PS1WT/WT, four
resent the average of four untreated PS1WT/WT and three Rab11 shRNA-treated
0.0001; APP density, p < 0.0001; APP intensity, p < 0.0001).
y (first inset) and approximately a 20% decrease in APP density (second inset).
our untreated PS1WT/WT and three Rab11 shRNA-treated PS1WT/WT biological
, p = 0.0018; APP intensity, p < 0.0001).
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Figure 3. PS1DE9 Neurons Exhibit Reduced Endocytosis and Transcytosis of APP and LDL
(A) Example images of the internalization of APP 22C11 antibody at 30min in PS1WT/WT and PS1DE9/DE9 neurons. The bar graphs depict the average APP punctum
count and average intensity normalized to cell area at 30 min (PS1WT/DE9, p = 0.1341; PS1DE9/DE9, p < 0.0001), 120 min (PS1WT/DE9, p < 0.0001; PS1DE9/DE9, p <
0.0001), and 240 min (PS1WT/DE9, p = 0.0024; PS1DE9/DE9, p < 0.0001). Data represent the mean ± SEM of a minimum of 50 neurons per time point from four
PS1WT/WT, four PS1WT/DE9, and four PS1DE9/DE9 biological replicates. Scale bar, 10 mm.
(B) Example images of LDL-BODIPY labeling in PS1WT/WT and PS1DE9/DE9 neurons. The graphs depict quantification of the LDL punctum count and intensity
normalized to cell area. As shown, PS1WT/DE9 and PS1DE9/DE9 neurons have reduced APP and LDL soma endocytosis, with the LDL defect appearing
most prominently at 240 min. Punctum data represent the pooled mean ± SEM or median with Tukey whiskers of over 140 cells/time point and 4–6 biological
(legend continued on next page)
764 Cell Reports 17, 759–773, October 11, 2016
A BMap2 LDL Map2 / LDL
w
t/w
t
w
t/w
t+
R
ab
11
KD
Actin
Rab11
CTRL SH1 SH2 SH3
C
D
CTRL Rab11KD
0.00
0.02
0.04
0.06
0.08
Av
er
ag
e
LD
L
Pu
nc
ta
C o
u n
t/A
re
a
at
4h
wt/wt****
CTRL Rab11KD
0.0
0.5
1.0
1.5
Ra
b1
1
Ax
on
al
De
ns
ity
(c
ou
nt
/u
m
)
****
CTRL Rab11 KD
0.0
0.5
1.0
1.5
LD
L
Ax
on
al
De
ns
ity
(c
ou
nt
/u
m
)
N.D.
Rab11 KDwt/wt
LDL
Rab11
515 161
11 15 33
Figure 4. Rab11 Mediates Endocytosis and Transcytosis of LDL
(A) PS1WT/WT neurons were transduced with a lentivirus containing control (CTRL) or Rab11 shRNA (Rab11 knockdown [KD]) and then treated with LDL for 4 hr.
Rab11 KD data represent mean ± SEM of soma obtained from three biological replicates of PS1WT/WT (p < 0.0001). Scale bar, 10 mm.
(B) Western blot of cells transduced with control or one of three different Rab11 shRNAs.
(C) PS1WT/WT axons and PS1WT/WT axons with Rab11 knockdown and co-stains. Scale bar, 5 mm.
(D) Vesicle densities of Rab11 and LDL under control and Rab11 knockdown conditions. For the LDL density graph, Rab11 knockdown (KD) resulted in non-
detectable (N.D.) levels of axonal LDL. The puncta seen in Rab11 KDwere the result of background autofluorescence. LDL transcytosis data represent themean ±
SEM of three biological replicates.
See also Figure S4.(Figure 3E). These results suggest that the reduction in basal
axonal APP in PS1DE9 neurons is due to a decrease in a consti-
tutive transcytosis pathway.
Rab11 Mediates Transcytosis of APP and LDL
To further investigate the role of Rab11 in endocytosis of
LDL and transcytosis of APP and LDL, we used shRNA-medi-
ated knockdown of Rab11 in wild-type neurons (Figure 4B).
Knockdown of Rab11 in PS1WT/WT neurons almost completely
abolished LDL endocytosis in the somatodendritic regionreplicates/genotype/time point at 30 min (PS1WT/DE9, p = 0.0671; PS1DE9/DE9, p
(PS1WT/DE9, p < 0.0001; PS1DE9/DE9, p < 0.0001), and 240 min (PS1WT/DE9, p < 0.
(C) Example images and a graph of intensity quantification are depicted for endo
represent the mean ± SEM of soma intensities across 23–28 images/time point r
replicates at 30 min (PS1WT/DE9, p = 0.1683; PS1DE9/DE9, p = 0.6532), 60 min (PS
PS1DE9/DE9, p = 0.5285), and 240 min (PS1WT/DE9, p = 0.1595; PS1DE9/DE9, p = 0.
(D and E) Neurons were grown in microfluidic devices and then allowed to interna
0.0011) or LDL-BODIPY (E) (densities: PS1WT/DE9, p < 0.0001; PS1DE9/DE9, p = 0.00
were p < 0.0001. Axons that passed through the channels were imaged, and punct
four PS1WT/WT, three PS1WT/DE9, and four PS1DE9/DE9 biological replicates per st
See also Figure S3.(Figure 4A), and transcytosed LDL was undetectable under
Rab11 knockdown conditions (Figures 4C and 4D). Further
support for a role of Rab11-mediated transcytosis of APP
comes from co-staining experiments where axonal transcy-
tosed APP (22C11) was stained with Rab11. As seen in Fig-
ure S4, 35% of Rab11 overlapped with transcytosed APP in
PS1WT/WT axons, and about 25% of transcytosed APP over-
lapped with Rab11 in PS1WT/WT axons. The percentage of
Rab11 with transcytosed 22C11 was reduced in PS1DE9/DE9
axons (as expected given the reduced density of transcytosed= 0.1637), 60 min (PS1WT/DE9, p = 0.0013; PS1DE9/DE9, p < 0.0001), 120 min
0001; PS1DE9/DE9, p < 0.0001). Scale bar, 20 mm,
cytosis of the fluid-phase fixable marker Dextran-tetramethylrhodamine. Data
epresenting eight PS1WT/WT, eight PS1WT/DE9, and eight PS1DE9/DE9 biological
1WT/DE9, p = 0.6265; PS1DE9/DE9, p = 0.8126), 120 min (PS1WT/DE9, p = 0.9117;
6465). Scale bar, 20 mm.
lized either APP antibody (D) (densities: PS1WT/DE9, p < 0.0001; PS1DE9/DE9, p =
24) on the soma sidewith the axons in fluidic isolation. All intensity comparisons
umdensities and intensities were evaluated. Data represent themean ±SEMof
ain. Scale bar, 5 mm.
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Figure 5. PS1DE9 Impairs Recycling of LRP1
(A) LRP1 protein andmRNA levels weremeasured before and after 4 hr of LDL treatment. PS1DE9 LRP1 protein was not different without (p = 0.1064) andwith 4-hr
LDL treatment (p = 0.4395), nor were PS1DE9 LRP1 mRNA levels in untreated (p = 1.0) and 4-hr LDL-treated neurons (p = 0.4627). Data represent mean ± SEM of
four biological replicates.
(B) Surface LDL levels were not different in PS1DE9 neurons after 4 hr of LDL treatment (p = 0.5793). Data represent mean ± SEM of soma values from 12
PS1WT/WT, 12 PS1WT/DE9, and 12 PS1DE9/DE9 biological replicates. Scale bar, 20 mm.
(C) PS1DE9/DE9 LRP1 surface levels, identified in the pull-down (PD) lane, were not different at baseline but trended to lower compared with PS1WT/WT after 4-hr
LDL treatment, although the results did not reach significance (p = 0.129) Whiskers depict mean ± SEM of three biological replicates per condition.
See also Figure S5.22C11), but the percent of 22C11 with Rab11 remained steady
(Figure S4A).
PS1DE9 Impairs Recycling of LRP1
The absence of a lipoprotein endocytic defect at early time
points in PS1DE9 neurons suggested that transcription, levels,
degradation, or recycling of the LDL receptor may be driving
the reduction in transcytosis. Although there are many po-
tential LDL receptors, LRP1 was an attractive candidate
because of its high expression in brain and neuronal samples
(Zhang et al., 2014). To determine whether transcription or
degradation of LRP1 was affected in PS1DE9 neurons, we
treated purified human neurons with unlabeled LDL and har-
vested neurons for mRNA and protein. We did not observe
differences in LRP1 mRNA or protein levels (Figure 5A) at
baseline or after LDL treatment, suggesting that transcription,
total levels, and degradation of LRP1 after LDL treatment are
not playing a role in the reduced endocytosis of LDL. Although766 Cell Reports 17, 759–773, October 11, 2016PS1 has been hypothesized to drive reduced degradation of
proteins because of alterations in lysosomal pH (McBrayer
and Nixon, 2013; Nixon and Yang, 2011), we did not observe
changes in lysosomal pH in the PS1DE9 neurons, as assessed
by the two ratiometric pH probes LysoSensor yellow/blue
dextran and fluorescein-Dextran-tetramethylrhodamine (Fig-
ure S5A). In addition, degradation of full-length APP is not
different in PS1DE9/DE9 neurons treated with cycloheximide
(Figure S5B) or when lysosome degradation is blocked with
chloroquine.
To determine whether the amount of lipoprotein receptors at
the somatodendritic surface are driving endocytosis defects
at later time points, we measured the LDL receptor amount at
baseline and after 4 hr of LDL treatment using two different
methods. Purified neurons were incubated at 4C with labeled
LDL for 30 min and then fixed (0-h time point); this gives a mea-
sure of total LDL receptors at the cell surface (Figure 5B). Neu-
rons were also incubated for 4 hr with unlabeled LDL and then
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brought to 4C, unlabeled LDL was washed off, and then cells
were incubated with labeled LDL followed by fixation. This gives
a measure of LDL receptors at the surface after 4 hr of endocy-
tosis (Figure 5B). Under these conditions, there were no differ-
ences in surface LDL punctum count in PS1DE9/DE9 neurons
compared with PS1WT/WT neurons (Figure 5B). Because LDL
could be binding non-specifically to surface proteins, we evalu-
ated specific receptor populations by biotinylating the surface
of neurons with a cleavable biotin and used streptavidin beads
to pull down surface proteins before and after LDL treatment.
Probing for LRP1 demonstrated that the surface levels of LRP1
at baseline were not significantly different between PS1WT/WT
and PS1DE9/DE9. However, after 4 hr of LDL treatment, LRP1 re-
ceptor levels trend to decrease in PS1DE9/DE9 (p = 0.1293) (Fig-
ure 5C). Thus, the decrease in LDL endocytosis we observed
in PS1DE9/DE9 neurons (Figure 3B) can be accounted for in part
by the modest (50%) LRP1 reduction at the neuronal surface
after 4 hr of LDL treatment.
LDL Endocytosis Defects in PS1DE9 Neurons Are
Rescued by b-Secretase Inhibition
We demonstrated previously that the PS1DE9 mutation impairs
g-secretase activity and that APP CTFs accumulate in human
PS1DE9 neurons (Woodruff et al., 2013). A previous study also
demonstrated that g-secretase inhibition in mouse embryonic
fibroblasts (MEFs) reduces LDL endocytosis (Tamboli et al.,
2008). To determine whether g-secretase activity or the b-CTF
fragment might be responsible for the impaired LDL endocytosis
in human neurons, we treated PS1WT/WT neurons with b- and
g-secretase inhibitors and measured LDL endocytosis (Figures
6A and 6B). Inhibition of g-secretase severely decreased LDL
endocytosis at 4 hr, whereas b-secretase inhibition had no signif-
icant effect (Figures 6A and 6B). Treatment with both b-
and g-secretase inhibitors caused a marked accumulation of
a-CTFs while ablating b-CTFs (Figure 6C) but had no effect on
LDL endocytosis at 4 hr (Figure 6B). These results suggest that
the b-CTF, not a-CTF, of APP is responsible for impairing LDL
endocytosis in DE9 neurons. To further test this possibility,
we treated PS1DE9 neurons with a b-secretase inhibitor and
measured LDL endocytosis (Figures 6A and 6D). We observed
that, upon treatment with a b-secretase inhibitor, PS1DE9/DE9
neurons were rescued in the ability to endocytose LDL (Fig-
ure 6D). Treatment of PS1DE9/DE9 neurons with both b- and
g-secretase inhibitors, which abolishes b-CTF and increases
a-CTF, also rescued the LDL endocytosis defect (Figure 6D),
which suggests that accumulation of only the b-CTF is respon-Figure 6. LDL Endocytosis Defects in PS1DE9 Neurons Are Rescued by
(A) Example images from drug-treated PS1WT/WT, PS1WT/DE9, and PS1DE9/DE9 ne
(B) Quantification of LDL punctum count per soma in 4-hr LDL-treated PS1WT/WT
LDL endocytosis in PS1WT/WT neurons, whereas treatment with a b-secretase inhi
100 nM (p < 0.0001), 6 GSI 1mM (p < 0.0001), 12 BSI 4 mM (not significant [n.s.]),
(C) Example western blot of neurons treated with b- and g-secretase inhibitors. a
(D) Quantification of LDL endocytosis in PS1DE9/DE9 neurons treatedwith inhibitors
4 mM BSI + 1 mM GSI biological replicates (***p < 0.0001 compared with vehicle)
(E) Quantification of LDL transcytosis in PS1DE9/DE9 under control and b-secretas
axonal LDL compared with untreated PS1DE9/DE9 from an average density of 0.
(F) Example images of PS1DE9/DE9 axons with and without b-secretase inhibition
SMI31 for neurofilament-H.
768 Cell Reports 17, 759–773, October 11, 2016sible for impaired LDL endocytosis. To test whether b-secretase
inhibition could rescue the transcytosis defect we observed, we
treated PS1DE9/DE9 neurons grown in microfluidic compartments
with a b-secretase inhibitor and then measured LDL transcytosis
(Figures 6E and 6F). Similar to the endocytosis result, we also
observed that b-secretase inhibition significantly increased the
amount of transcytosed LDL in PS1DE9/DE9 neurons (Figure 6E).
LDL Endocytosis Defects Are Common to fAD APP
Mutations
Accumulation of APP b-CTFs is a phenotype shared by many
APP and PS1 fAD mutations (Chang and Suh, 2005; Sinha and
Lieberburg, 1999). To assess whether other fADmutations might
share a common phenotype of impaired LDL endocytosis, we
generated additional isogenic cell lines harboring either the
APP V717F (APPV717F) or APP Swedish (APPswe) mutations
(Sherrington et al., 1995). In neurons homozygous for the
APPV717F mutation, there was significantly reduced LDL endo-
cytosis after 4 hr, and this defect was rescued by b-secretase
inhibition (Figures 7A and 7B). Similar to both the PS1DE9 and
APPV717F mutations, neurons homozygous for the APPswe muta-
tion also exhibited decreased LDL endocytosis (Figures 7A and
7B). In contrast to the other fADmutations, b-secretase inhibition
in the APPswe neurons did not rescue the LDL endocytosis defect
(Figures 7A and 7B). However, mutant APP Swedish protein has
been reported previously to decrease the potency of b-secretase
inhibitors (Yamakawa et al., 2010), which could explain why,
in our study, b-secretase inhibition did not rescue the APPswe
neurons. These findings demonstrate that the reduction in LDL
endocytosis is not specific to the PS1DE9 mutation but is a
phenotype common to fAD APP mutations. Similar to PS1DE9
axons, we also observed reduced basal levels of axonal APP
and Rab11 densities and reduced endocytosis of 22C11 at
4 hr in APPV717F neurons (Figure S6). Thus, endocytosis defects,
and perhaps transcytosis defects, are common among at least
one fAD PS1 mutation and two fAD APP mutations.
DISCUSSION
Here we demonstrate that, in human neurons with endogenous
expression of fAD mutations induced with genome editing
technology, increased b-CTF of APP alters the subcellular local-
ization of APP and the distribution of Rab11 and decreases
endocytosis and soma-to-axon transcytosis of LDL. LDL endo-
cytosis and transcytosis defects are rescued by b-secretase in-
hibition in at least some of the fAD mutations. Our results showb-Secretase Inhibition
urons. Scale bar, 20 mm.
neurons. Treatment with a g-secretase inhibitor (GSI) resulted in a decrease in
bitor (BSI) had no effect. Data represent the mean ± SEM of 12 PS1WT/WT, 6 GSI
and 4 GSI 1 mM + BSI 4 mM (n.s) biological replicates.
-CTFs and b-CTFs are indicated by arrows.
. n = 10 PS1DE9/DE9 for vehicle (VEH), 12 PS1DE9/DE9 for BSI, and 4 PS1DE9/DE9 for
.
e inhibition. Treatment with 4 mM of BSI increased the levels of transcytosed,
33 count/mm to 0.43 count/mm (p = 0.0044).
after 4 hr of LDL transcytosis. Axons were co-stained with the axonal marker
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Figure 7. LDL Endocytosis Defects Are Common in Other fAD Mutations
(A) Representative images of LDL uptake in APPv717f and APPswe neurons co-stained with the somatodendritic marker Map2. Scale bar, 20 mm.
(B) Quantification of LDL punctum count after 4 hr of LDL treatment in APPWT/WT, APPV717F/V717F, and APPswe/swe neurons with vehicle and 4 mM BSI treatment
demonstrates that APPmutations also result in decreased LDL uptake (APPV717F/V717F, p = 0.0009; APPswe/swe, p < 0.0001), which is rescuedwith BSI treatment in
APPV717F (APPV717F/V717F, p = 0.5545) but not APPswe. Data represent the mean ± SEM of six APPWT/WT, three APPV717F/V717F, and three APPswe/swe biological
replicates.
(C) Model of APP and lipoprotein transcytosis in neurons.
(C1) FL-APP is internalized in Rab5+ sorting endosomes that contain LDL associated with LRP1 as well as b-secretase (BACE1) and possibly PS1.
(C2) As vesicles become more acidic along the endocytic pathway, LDL dissociates from LRP1, and FL-APP is cleaved by b-secretase. A proportion of the
cleaved APP population resides in Rab11+ endosomes containing LRP1, b-CTF, and LDL.
(C3) When b-CTF is cleaved by g-secretase, LRP1 can be recycled back to the cell surface, and transcytosis of LDL and FL-APP to the axon can occur. fAD
mutations increase b-CTFs either by enhancing b-secretase processing or impairing g-secretase-mediated cleavage of APP. b-CTFs impair recycling of LRP1
and decrease transcytosis of APP and lipoproteins, possibly by directly sequestering LRP1 in a Rab11+ endosome.
See also Figure S6.that impaired LDL endocytosis and transcytosis are present in
multiple types of fAD mutations, (Figure 7C) and that together
they define an apparent defect in the Rab11 recycling endo-some. Epidemiologic evidence implicating cholesterol as amajor
player in AD also dovetails with these molecular and cellular
findings (reviewed in Fonseca et al., 2010, and Wolozin, 2004).Cell Reports 17, 759–773, October 11, 2016 769
We demonstrate that APP b-CTFs may cause impaired LDL
uptake by reducing recycling of LRP1 receptors back to the
cell surface. One possible mechanism is that b-CTFs bind to
LRP1 (Kounnas et al., 1995; Pietrzik et al., 2002; Tamboli et al.,
2008), or other LDL receptors and retain LDL receptors in a
Rab11-containing compartment until the b-CTF is cleaved by
g-secretase. This would possibly explain why g-secretase inhibi-
tion impairs LDL uptake and why that defect can be rescued by
b-secretase inhibition. The observation that basal Rab11 is
reduced in axons of fAD mutant neurons suggests that a com-
mon constitutive recycling/transcytotic pathway is impaired
and raises the possibility that modulating Rab11 activity could
also rescue fAD phenotypes. Although we cannot rule out prote-
olysis of the 22C11 or labeled LDL probe following endocytosis
as a possible explanation for the reduced transcytosis, our
data are most consistent with the possibility reported in previous
work that early endocytosis is affected (Cataldo et al., 2000).
The finding that fAD neurons have defects in lipoprotein trans-
cytosis is intriguing in light of previous work showing that neu-
rons are dependent on the uptake of extracellular cholesterol
from lipoprotein particles to perform functions such as axon
elongation and synapse formation and maintenance (Barres
and Smith, 2001; Lane-Donovan et al., 2014; Mauch et al.,
2001; Na¨gler et al., 2001; Pfrieger, 2003; Pierrot et al., 2013). In
fact, glia-derived cholesterol was reported to enhance synapto-
genesis of the adult rat CNS (Mauch et al., 2001; Na¨gler et al.,
2001), suggesting that a defect in endocytosis and transcytosis
of extracellularly derived cholesterol could have long-term
functional consequences leading to impaired neurotransmitter
release and synaptic function. For instance, many studies of
APOE function have focused on its potential role in mediating
Ab clearance, but APOE has also been identified as the major
lipoprotein carrier in the brain, and the e4 allele is less efficient
in transporting brain cholesterol (Liu et al., 2013). Interestingly,
post-mortem studies comparing sAD patients to age-matched
controls found that brain cholesterol levels are reduced in the
areas of learning and memory, the hippocampus and cortex
(Svennerholm and Gottfries, 1994).
Previous work implicated early endosome dysfunction in sAD
and some forms of fAD (Cataldo et al., 2001; Ginsberg et al.,
2010). In contrast to previous studies, we report abnormalities
in a Rab11-marked recycling endosome in fAD mutations, which
is consistent with previous work on transcytosis that identified
Rab11 as an endocytic regulator with a unique role in polarized
cells, including neurons (Ascan˜o et al., 2009; Buggia-Pre´vot
et al., 2014; Welz et al., 2014). Thus, we describe a defect in a
neuron-specific pathway that could contribute to the reported
early endosomal defects and could produce AD pathology. In
contrast, other recent findings have suggested that lysosomal
pathology is the major driver of pathology in PS1 fAD mutations
(Lee et al., 2010, 2015). Our data suggest that dysfunction in en-
dosomal sorting could drive changes in lysosomal function
rather than an original defect in the lysosome that drives such
changes (Peric and Annaert, 2015).
We thus propose that transcytotic trafficking defects could be
at the root of many types of fAD and, potentially, sAD. In fact, en-
docytic trafficking changes have been reported for APOE4 rela-
tive to APOE3 and 2 (Chen et al., 2010). These types of defects770 Cell Reports 17, 759–773, October 11, 2016could lead to previously reported axonal amyloid-dependent
and -independent transport defects (Kim et al., 2015; Stokin
et al., 2008; Vossel et al., 2015). Similarly, many fAD mutations
thought to act solely by changing Ab production may, in fact,
also act by changing sorting and trafficking signals in b-CTF of
APP, leading to changes in constituents of axonal vesicles
derived by transcytotic trafficking of lipoproteins and other key
synaptic constituents. Although it may seem counter-intuitive
that cleavage of b-CTF is needed to generate axonal vesicles
containing b-CTF or full-length APP, we suggest that b-CTF
cleavage happens in the portion of the recycling endosome
that remains in the soma and that buds off axonal vesicles with
APP, lipoproteins, and other components (Figure 7C). Finally,
we note that the defects we report occur in the absence of
overexpression of any of the proteins involved and, thus, may
accurately reflect the earliest changes from normal behavior
generated by fAD.
EXPERIMENTAL PROCEDURES
Statistical Methods
Statistics were performed using GraphPad Prism. Normality for each dataset
was assessed using D’Agostino-Pearson test. When data were normally
distributed, a two-way ANOVA with a post hoc Tukey test was used to
compare genotypes. For precise p value comparisons, a multiple t test was
done after ANOVA calculations. Most immunofluorescence data were non-
normally distributed, and a nonparametric Kruskal-Wallis test with Dunn’smul-
tiple comparison was used to compare genotype medians. Data are depicted
with bar graphs of the mean ± SEM of all values in an experiment or boxplots
where the median is depicted with a line, and whiskers indicate the Tukey
distribution as determined by GraphPad Prism.
Microfluidic Compartments
Microfluidic compartments were made in-house as described previously (Nie-
derst et al., 2015). Briefly, Sylgard 182 (Ellsworth Adhesives) was used to mold
devices. When cured, the devices were cut and then washed with isopropanol,
water, and 70% ethanol. The devices were plasma-treated and mounted onto
glass coverslips. The mounted device was this coated with poly-ornithine/
laminin (PO/L) as described above.
sAPP Measurements
sAPP was measured from conditioned media frommicrofluidic compartments
from the soma side (contained soma, axons, dendrites) and the axon side
(axons only) 48 hr after a full medium change in which the axons were kept
in fluidic isolation. sAPP was measured using the sAPPa/sAPPb human kit
(Meso Scale Discovery). The kit has a sensitivity down to 120 pg/mL for sAPPa
and 52 pg/mL for sAPPb, and all measurements were in the linear range.
Immunofluorescence
Purified neurons were grown in 384-well imaging plates at a density of 25,000
cells/well for 7–9 days after sorting. Neurons were fixed in 4% paraformalde-
hyde and PBS for 30 min at 37C, permeabilized with 0.1% Triton X-100, and
blocked (10% donkey serum, 3% BSA, and 0.1% Triton X-100 in PBS). For
surface labeling experiments, neurons were not permeabilized. For compart-
ment experiments, polydimethylsiloxane (PDMS) microfluidic devices were
plasma-bonded directly onto glass coverslips (Niederst et al., 2015). Neurons
were seeded at a density of one to three million cells per compartment
and grown for 7–10 days (until axons passed through the channels). Com-
partments were then fixed as above and imaged. The antibodies used
for immunofluorescence experiments were anti-Rab11 (1:1,000, Life Tech-
nologies, 71-5300), anti-APP Y188 (1:200, Abcam, ab32136), anti-APP
22C11 (1:100, EMD Millipore, MAB348), anti-EEA1 (1:100, BD 610457), anti-
NF-H (1:1,000, BioLegend, SMI-31r), and anti-Map2 (1:500, ab5392). Sec-
ondary antibodies were Alexa Fluor donkey anti-mouse and anti-rabbit
immunoglobulin G (IgG) (Invitrogen), and Dylight 405 donkey anti-chicken IgY
(Jackson ImmunoResearch Laboratories, 703-475-155) was used at 1:200.
Images were acquired on a Zeiss confocal microscope.
Endocytosis and Transcytosis
For constitutive uptake endocytosis assays, neurons were incubated
with LDL-boron-dipyrromethene (BODIPY) (20 mg/mL, Invitrogen L3483)
or Dextran-tetramethylrhodamine (TMR), molecular weight (MW) 10,000
(250 mg/mL, Invitrogen, D1817) at 37C for the indicated times, fixed, and
imaged. For all fixed endocytosis assays, a custom ImageJ program was
used to identify Map2-positive soma and automatically generate regions of in-
terest (ROIs) corresponding to soma. Mean intensity and punctum count per
soma were determined and averaged across images and experiments. All
endocytosis assays were repeated at least three times. In experiments where
secretase inhibitors were used, cells were treated with the inhibitor 24 hr prior
to the experiment and kept in the presence of the inhibitor for the duration of
the experiment. Compound E (GSI, EMD Chemicals) was used at 200 nM in
endocytosis assays and at 100 nM and 1 mM for western blotting. bIV inhibitor
(b Inh, Millipore) was used at 4 mM.
For transcytosis experiments, neurons were grown in compartments and
treated on the soma side with LDL-BODIPY (20 mg/mL), LDL-DiI (1,1’diocta-
decyl-3,3,3’,3-Tetramethyllindocarbocycanine Percholorate) (12.5 mg/mL), or
mouse anti-22C11 (1:100) for 4 hr with axons in fluidic isolation. Axonal punc-
tum analysis was done as described previously (Szpankowski et al., 2012).
Axons were imaged at 3100, and a custom Gaussian-fitting colocalization
package in MATLAB (MathWorks) was used to calculate axonal density, punc-
tum intensity, and percent colocalization per axon. All iPSCs were generated
following informed consent and Institutional Review Board approval.
Surface Biotinylation Assay
Neuronal medium was changed to warm fresh medium or medium supplanted
with 12.5 mg/mL of unlabeled LDL for 4 hr. At the end of the incubation, neurons
were washed twice with ice-cold PBS and then incubated at 4C with 2 mM
EZ-Link Sulfo-NHS-SS-Biotin (Life Technologies) in PBS for 30 min. Cells
were then lysed in equal volumes of radioimmunoprecipatation assay lysis
(RIPA) buffer. For pull-down experiments, 200 mg of harvested protein at
0.5 mg/mL was incubated with 50 mL of pre-washed Pierce streptavidin mag-
netic beads (Life Technologies, 88817) overnight at 4C. The next day, beads
were washed to remove residual, unbound proteins, and biotinylated proteins
were released from the streptavidin beads by boiling samples in loading buffer
at 100C. Western blots were run with 5% of input, 5% of supernatant, and
50% of pull-down. Quantification of recycling was determined based on input
signal (pull-down/input).
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